Penumbra, Inc. (PEN) Stock Price & Analysis

Penumbra, Inc. (PEN) closed at USD 324.96 on Thursday, October 22, 2026, up 0.43% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 323.56; the Oct 22, 2026 session ranged USD 323.67–325.45 on volume of 469,941 shares. Market capitalization is $12.80B, with a 52-week range of USD 221.26–362.41 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:58 UTC.

Also available as compact Markdown for AI agents: nexqual.com/PEN.md

Key facts (PEN)

• Last four reported quarters (through Jun 30, 2026): revenue $1.50B, net income $161M (10.7% margin), free cash flow $216M (SEC filings).
• Valuation: P/E 79.7x (avg 280.9x at the last 3 fiscal year-ends).
• Insider open-market sales, last ~7 months: 1 Form 4 filings, $33K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 2.76 on a 1–5 scale) (17 analysts), mean target USD 362.54 (range 320–374).
• Total return with dividends: 1Y +28.2% vs S&P 500 +14.9%; 5Y +16.5% vs S&P 500 +80.3%.
• Next earnings: 2026-11-04, EPS estimate USD 1.18, revenue estimate $400M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PEN)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (PEN)

P/E 79.7x · P/S 8.5x · P/FCF 59.3x · P/B 8.4x · FCF yield 1.69% · Earnings yield 1.25%

P/E at fiscal year-ends: Dec 2025 68.8x, Dec 2024 665.5x, Dec 2023 108.5x.

Insider sales (SEC Form 4, open-market, last ~7 months) (PEN)

1 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (PEN)

Consensus Hold (mean 2.76 on a 1–5 scale), 17 analysts; mean target USD 362.54 (low 320, high 374).

Rating changes, last 120 days:

Total return (dividends reinvested) (PEN)

PEN revenue by product line (quarter ended Jun 30, 2026)

PEN revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

PEN suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 25, 2026.

Companies that name PEN in their SEC reports

PEN company outlook (results filed Jul 30, 2026)

• “Financial Outlook and Webcast and Conference Call Information Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended June 30, 2026.”

Quoted word-for-word from the SEC 8-K results press release.

PEN analyst estimates and revisions

PEN options: expected move

Options price a move of about ±13.6% (±$44.30) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±7.1% on average.

30-day implied volatility 41.8% vs 5% realized over the last 30 trading days. Put/call ratio (volume) 5.11. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:58 UTC)

Technical Analysis (PEN)

Nexqual's technical model rates PEN "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:58 UTC.

Analyst Ratings (PEN)

Wall Street analysts rate PEN "Hold" based on 17 analysts, with a mean price target of USD 362.54 (range USD 320–374), per Nexqual as of October 23, 2026 at 09:58 UTC.

Earnings (PEN)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:58 UTC.

Financials & Fundamentals (PEN)

Source: Nexqual, October 23, 2026 at 09:58 UTC.

Financial Health Score (PEN)

Nexqual rates Penumbra, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:58 UTC.

Ownership (PEN)

Source: Nexqual, October 23, 2026 at 09:58 UTC.

Leadership (PEN)

Penumbra, Inc. is led by Adam Elsesser, Co-Founder, Chairman & CEO, per Nexqual as of October 23, 2026 at 09:58 UTC.

Major Backers & Investors (PEN)

Notable institutional backers of Penumbra, Inc. include HBK Investments L P, ExodusPoint Capital Management, LP, Balyasny Asset Management LP, according to Nexqual as of October 23, 2026 at 09:58 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:58 UTC.

From Penumbra, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• We developed our proprietary aspiration source as a fully-integrated system specifically for mechanical thrombectomy by vacuum aspiration.
• Penumbra System Reperfusion Catheters are the cornerstone of the Penumbra System and are manufactured using a variety of proprietary processes and materials science innovations for use in revascularization of patients with acute ischemic stroke.
• Our success depends in part on our ability to protect our proprietary technology and intellectual property and operate without infringing the patents and other proprietary rights of third parties.
• We also seek to protect our proprietary rights through a variety of other methods, including confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and others who may have access to our proprietary information.

Legal & Regulatory Risks (Item 1A, quoted)

• We are subject to stringent domestic and foreign medical device regulations, which may impede the approval or clearance process for our products, hinder our development activities and manufacturing processes and, in some cases, result in the recall or seizure of previously approved or cleared products.
• We may not receive necessary foreign regulatory approvals or clearances or otherwise comply with foreign regulations.
• Our global regulatory environment is becoming increasingly stringent and unpredictable, which could increase the time, cost and complexity of obtaining regulatory approvals for our products, as well as the clinical and regulatory costs of supporting those approvals.
• We may not be able to meet regulatory quality requirements applicable to our manufacturing process.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:58 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt